South Korean pharmaceutical HLB Co. is poised to venture into new therapeutic areas, including chimeric antigen receptor T cell, or CAR-T cell therapy, and a glioblastoma treatment, according to Chairman Jin Yang-gon. 

Please refer to the following website for further details: HLB on a quest for next-generation target cancer therapy CAR-T: CEO interview (naver.com)